Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Lloydspharmacy chief Cormac Tobin resigns

Cormac Tobin, managing director of Lloydspharmacy's parent company Celesio UK, has left the company “with immediate effect”, the multiple has announced.

His departure comes just one week after Mr Tobin – who had been with the Celesio group for more than 10 years – told Lloyds employees that 190 “commercially unviable” branches of the multiple would have to close or be sold.

Celesio UK said the remaining members of its board would manage the business “whilst a successor is sought”.

Brian Tyler, chairman of the management board of McKesson Europe – which owns Celesio – said Mr Tobin had “built a strong leadership team for Celesio UK”, and added “his warm and engaging personality made him many friends across community pharmacy and beyond”.

“I am grateful for the dedication that Cormac has shown over the last few years and his leadership through an ever-changing external environment,” Mr Tyler said.

Read C+D's exclusive interview with Cormac Tobin from earlier this year.

What do you make of Cormac Tobin's departure?

Related Content

Topics



Pharmacist Managers - Recruiting Now !
East London, Essex and Luton
£40,000 - £50,000 per year

Apply Now
UsernamePublicRestriction

Register

CD009029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel